tiprankstipranks
Terns Pharmaceuticals (TERN)
NASDAQ:TERN
US Market
Want to see TERN full AI Analyst Report?

Terns Pharmaceuticals (TERN) Stock Forecast & Price Target

540 Followers
See the Price Targets and Ratings of:

TERN Analyst Ratings

Hold
6Ratings
Hold
0 Buy
6 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Terns
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TERN Stock 12 Month Forecast

Average Price Target

$52.97
▲(0.61% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Terns Pharmaceuticals in the last 3 months. The average price target is $52.97 with a high forecast of $53.00 and a low forecast of $52.89. The average price target represents a 0.61% change from the last price of $52.65.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","15":"$15","28":"$28","41":"$41","54":"$54"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$53.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52.9725,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$52.97</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52.89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$52.89</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,15,28,41,54],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,52.93,52.93538461538461,52.94076923076923,52.94615384615385,52.95153846153846,52.956923076923076,52.96230769230769,52.96769230769231,52.973076923076924,52.97846153846154,52.98384615384615,52.98923076923077,52.994615384615386,{"y":53,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,52.93,52.93326923076923,52.93653846153846,52.93980769230769,52.94307692307692,52.94634615384615,52.949615384615385,52.95288461538461,52.956153846153846,52.95942307692307,52.96269230769231,52.965961538461535,52.96923076923077,{"y":52.9725,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,52.93,52.926923076923075,52.923846153846156,52.92076923076923,52.917692307692306,52.91461538461539,52.91153846153846,52.90846153846154,52.90538461538461,52.902307692307694,52.89923076923077,52.896153846153844,52.893076923076926,{"y":52.89,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.85,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.47,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.81,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.26,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.53,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.82,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.03,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.79,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.93,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$53.00Average Price Target$52.97Lowest Price Target$52.89
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Oppenheimer Analyst forecast on TERN
Oppenheimer
Oppenheimer
$58$52.89
Hold
0.46%
Upside
Downgraded
04/27/26
Terns Pharmaceuticals downgraded to Perform from Outperform at OppenheimerTerns Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
Leerink Partners Analyst forecast on TERN
Leerink Partners
Leerink Partners
Hold
Downgraded
04/08/26
Terns Pharmaceuticals downgraded to Market Perform from Outperform at LeerinkTerns Pharmaceuticals downgraded to Market Perform from Outperform at Leerink
Barclays Analyst forecast on TERN
Barclays
Barclays
$53
Hold
0.66%
Upside
Assigned
03/31/26
Barclays Keeps Their Hold Rating on Terns Pharmaceuticals (TERN)
Mizuho Securities Analyst forecast on TERN
Mizuho Securities
Mizuho Securities
$54$53
Hold
0.66%
Upside
Downgraded
03/27/26
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Terns Pharmaceuticals (TERN)
H.C. Wainwright Analyst forecast on TERN
H.C. Wainwright
H.C. Wainwright
$60$53
Hold
0.66%
Upside
Downgraded
03/25/26
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (NASDAQ: GUTS) and Terns Pharmaceuticals (NASDAQ: TERN)
Citizens JMP Analyst forecast on TERN
Citizens JMP
Citizens JMP
Hold
Downgraded
03/25/26
Terns Pharmaceuticals downgraded to Market Perform from Outperform at CitizensTerns Pharmaceuticals downgraded to Market Perform from Outperform at Citizens
Jefferies Analyst forecast on TERN
Jefferies
Jefferies
$35
Buy
-33.52%
Downside
Reiterated
12/08/25
Terns Pharmaceuticals (TERN) Gets a Buy from Jefferies
TD Cowen Analyst forecast on TERN
TD Cowen
TD Cowen
Buy
Reiterated
11/13/25
Terns Pharmaceuticals: Promising Clinical Results and Strong Financial Position Justify Buy Rating
Roth MKM Analyst forecast on TERN
Unknown Analyst
Roth MKM
Not Ranked
Roth MKM
$15
Buy
-71.51%
Downside
Initiated
09/17/25
Terns Pharmaceuticals (TERN) Gets a Buy from Roth MKM
J.P. Morgan Analyst forecast on TERN
J.P. Morgan
J.P. Morgan
$14
Hold
-73.41%
Downside
Reiterated
05/09/25
J.P. Morgan Remains a Hold on Terns Pharmaceuticals (TERN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Oppenheimer Analyst forecast on TERN
Oppenheimer
Oppenheimer
$58$52.89
Hold
0.46%
Upside
Downgraded
04/27/26
Terns Pharmaceuticals downgraded to Perform from Outperform at OppenheimerTerns Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
Leerink Partners Analyst forecast on TERN
Leerink Partners
Leerink Partners
Hold
Downgraded
04/08/26
Terns Pharmaceuticals downgraded to Market Perform from Outperform at LeerinkTerns Pharmaceuticals downgraded to Market Perform from Outperform at Leerink
Barclays Analyst forecast on TERN
Barclays
Barclays
$53
Hold
0.66%
Upside
Assigned
03/31/26
Barclays Keeps Their Hold Rating on Terns Pharmaceuticals (TERN)
Mizuho Securities Analyst forecast on TERN
Mizuho Securities
Mizuho Securities
$54$53
Hold
0.66%
Upside
Downgraded
03/27/26
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Terns Pharmaceuticals (TERN)
H.C. Wainwright Analyst forecast on TERN
H.C. Wainwright
H.C. Wainwright
$60$53
Hold
0.66%
Upside
Downgraded
03/25/26
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (NASDAQ: GUTS) and Terns Pharmaceuticals (NASDAQ: TERN)
Citizens JMP Analyst forecast on TERN
Citizens JMP
Citizens JMP
Hold
Downgraded
03/25/26
Terns Pharmaceuticals downgraded to Market Perform from Outperform at CitizensTerns Pharmaceuticals downgraded to Market Perform from Outperform at Citizens
Jefferies Analyst forecast on TERN
Jefferies
Jefferies
$35
Buy
-33.52%
Downside
Reiterated
12/08/25
Terns Pharmaceuticals (TERN) Gets a Buy from Jefferies
TD Cowen Analyst forecast on TERN
TD Cowen
TD Cowen
Buy
Reiterated
11/13/25
Terns Pharmaceuticals: Promising Clinical Results and Strong Financial Position Justify Buy Rating
Roth MKM Analyst forecast on TERN
Unknown Analyst
Roth MKM
Not Ranked
Roth MKM
$15
Buy
-71.51%
Downside
Initiated
09/17/25
Terns Pharmaceuticals (TERN) Gets a Buy from Roth MKM
J.P. Morgan Analyst forecast on TERN
J.P. Morgan
J.P. Morgan
$14
Hold
-73.41%
Downside
Reiterated
05/09/25
J.P. Morgan Remains a Hold on Terns Pharmaceuticals (TERN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Terns Pharmaceuticals

3 Months
xxx
Success Rate
9/14 ratings generated profit
64%
Average Return
+37.23%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +37.23% per trade.
1 Year
Ritu BaralTD Cowen
Success Rate
8/14 ratings generated profit
57%
Average Return
+215.31%
Copying Ritu Baral's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +215.31% per trade.
2 Years
xxx
Success Rate
12/14 ratings generated profit
86%
Average Return
+470.49%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +470.49% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TERN Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
8
3
3
1
0
Buy
27
16
8
4
1
Hold
0
0
9
12
16
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
35
19
20
17
17
In the current month, TERN has received 1 Buy Ratings, 16 Hold Ratings, and 0 Sell Ratings. TERN average Analyst price target in the past 3 months is 52.97.
Each month's total comprises the sum of three months' worth of ratings.

TERN Financial Forecast

TERN Earnings Forecast

The previous quarter’s earnings for TERN were -$0.30.
The previous quarter’s earnings for TERN were -$0.30.
No data currently available

TERN Sales Forecast

The previous quarter’s earnings for TERN were $0.00.
The previous quarter’s earnings for TERN were $0.00.

TERN Stock Forecast FAQ

What is TERN’s average 12-month price target, according to analysts?
Based on analyst ratings, Terns Pharmaceuticals’s 12-month average price target is 52.97.
    What is TERN’s upside potential, based on the analysts’ average price target?
    Terns Pharmaceuticals has 0.61% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is TERN a Buy, Sell or Hold?
          Terns Pharmaceuticals has a consensus rating of Hold which is based on 0 buy ratings, 6 hold ratings and 0 sell ratings.
            What is Terns Pharmaceuticals’s price target?
            The average price target for Terns Pharmaceuticals is 52.97. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $53.00 ,the lowest forecast is $52.89. The average price target represents 0.61% Increase from the current price of $52.65.
              What do analysts say about Terns Pharmaceuticals?
              Terns Pharmaceuticals’s analyst rating consensus is a Hold. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of TERN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.